Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant global health issue, affecting over 30% of the population worldwide due to the rising prevalence of metabolic risk factors such as obesity and type 2 diabetes mellitus. This spectrum of liver disease ranges from isolat...

Descripción completa

Detalles Bibliográficos
Autores: Saeed, Huma, Díaz, Luis Antonio, Gil Gómez, Antonio, Burton, Jeremy, Bajaj, Jasmohan S., Romero Gómez, Manuel, Khan, Mohammad Qasim
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/179236
Acceso en línea:https://hdl.handle.net/11441/179236
https://doi.org/10.3350/cmh.2024.0811
Access Level:acceso abierto
Palabra clave:Non-alcoholic fatty liver disease
Metabolic dysfunction-associated steatotic liver disease
Gut microbiota
Microbiome
Precision medicine
id ES_028dd696fbebe45ac3c8535fd4d2005e
oai_identifier_str oai:idus.us.es:11441/179236
network_acronym_str ES
network_name_str España
repository_id_str
spelling Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver diseaseSaeed, HumaDíaz, Luis AntonioGil Gómez, AntonioBurton, JeremyBajaj, Jasmohan S.Romero Gómez, ManuelKhan, Mohammad QasimNon-alcoholic fatty liver diseaseMetabolic dysfunction-associated steatotic liver diseaseGut microbiotaMicrobiomePrecision medicineMetabolic dysfunction-associated steatotic liver disease (MASLD) is a significant global health issue, affecting over 30% of the population worldwide due to the rising prevalence of metabolic risk factors such as obesity and type 2 diabetes mellitus. This spectrum of liver disease ranges from isolated steatosis to more severe forms such as steatohepatitis, fibrosis, and cirrhosis. Recent studies highlight the role of gut microbiota in MASLD pathogenesis, showing that dysbiosis significantly impacts metabolic health and the progression of liver disease. This review critically evaluates current microbiome-centered therapies in MASLD management, including prebiotics, probiotics, synbiotics, fecal microbiota transplantation, and emerging therapies such as engineered bacteria and bacteriophage therapy. We explore the scientific rationale, clinical evidence, and potential mechanisms by which these interventions influence MASLD. The gut-liver axis is crucial in MASLD, with notable changes in microbiome composition linked to disease progression. For instance, specific microbial profiles and reduced alpha diversity are associated with MASLD severity. Therapeutic strategies targeting the microbiome could modulate disease progression by improving gut permeability, reducing endotoxin-producing bacteria, and altering bile acid metabolism. Although promising, these therapies require further research to fully understand their mechanisms and optimize their efficacy. This review integrates findings from clinical trials and experimental studies, providing a comprehensive overview of microbiome-centered therapies’ potential in managing MASLD. Future research should focus on personalized strategies, utilizing microbiome features, blood metabolites, and customized dietary interventions to enhance the effectiveness of these therapies.Korean Association for the Study of the Liver (KASL)FisiologíaMedicinaFondo Nacional de Desarrollo Científico y Tecnológico. ChileInstituto de Salud Carlos III2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/179236https://doi.org/10.3350/cmh.2024.0811reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésClinical and Molecular Hepatology, 31, S94-S111.1241450CD23-00024https://doi.org/10.3350/cmh.2024.0811info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1792362026-06-17T12:51:07Z
dc.title.none.fl_str_mv Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease
title Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease
spellingShingle Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease
Saeed, Huma
Non-alcoholic fatty liver disease
Metabolic dysfunction-associated steatotic liver disease
Gut microbiota
Microbiome
Precision medicine
title_short Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease
title_full Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease
title_fullStr Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease
title_full_unstemmed Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease
title_sort Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease
dc.creator.none.fl_str_mv Saeed, Huma
Díaz, Luis Antonio
Gil Gómez, Antonio
Burton, Jeremy
Bajaj, Jasmohan S.
Romero Gómez, Manuel
Khan, Mohammad Qasim
author Saeed, Huma
author_facet Saeed, Huma
Díaz, Luis Antonio
Gil Gómez, Antonio
Burton, Jeremy
Bajaj, Jasmohan S.
Romero Gómez, Manuel
Khan, Mohammad Qasim
author_role author
author2 Díaz, Luis Antonio
Gil Gómez, Antonio
Burton, Jeremy
Bajaj, Jasmohan S.
Romero Gómez, Manuel
Khan, Mohammad Qasim
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Fisiología
Medicina
Fondo Nacional de Desarrollo Científico y Tecnológico. Chile
Instituto de Salud Carlos III
dc.subject.none.fl_str_mv Non-alcoholic fatty liver disease
Metabolic dysfunction-associated steatotic liver disease
Gut microbiota
Microbiome
Precision medicine
topic Non-alcoholic fatty liver disease
Metabolic dysfunction-associated steatotic liver disease
Gut microbiota
Microbiome
Precision medicine
description Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant global health issue, affecting over 30% of the population worldwide due to the rising prevalence of metabolic risk factors such as obesity and type 2 diabetes mellitus. This spectrum of liver disease ranges from isolated steatosis to more severe forms such as steatohepatitis, fibrosis, and cirrhosis. Recent studies highlight the role of gut microbiota in MASLD pathogenesis, showing that dysbiosis significantly impacts metabolic health and the progression of liver disease. This review critically evaluates current microbiome-centered therapies in MASLD management, including prebiotics, probiotics, synbiotics, fecal microbiota transplantation, and emerging therapies such as engineered bacteria and bacteriophage therapy. We explore the scientific rationale, clinical evidence, and potential mechanisms by which these interventions influence MASLD. The gut-liver axis is crucial in MASLD, with notable changes in microbiome composition linked to disease progression. For instance, specific microbial profiles and reduced alpha diversity are associated with MASLD severity. Therapeutic strategies targeting the microbiome could modulate disease progression by improving gut permeability, reducing endotoxin-producing bacteria, and altering bile acid metabolism. Although promising, these therapies require further research to fully understand their mechanisms and optimize their efficacy. This review integrates findings from clinical trials and experimental studies, providing a comprehensive overview of microbiome-centered therapies’ potential in managing MASLD. Future research should focus on personalized strategies, utilizing microbiome features, blood metabolites, and customized dietary interventions to enhance the effectiveness of these therapies.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/179236
https://doi.org/10.3350/cmh.2024.0811
url https://hdl.handle.net/11441/179236
https://doi.org/10.3350/cmh.2024.0811
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Clinical and Molecular Hepatology, 31, S94-S111.
1241450
CD23-00024
https://doi.org/10.3350/cmh.2024.0811
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Korean Association for the Study of the Liver (KASL)
publisher.none.fl_str_mv Korean Association for the Study of the Liver (KASL)
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402662986842112
score 15,812429

Similares en LA Referencia